Clinical trials: Metastatic NSCLC
Lung Cancer
Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness
The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy.
- Trial name
- NCT06292052
- Testing
- Immunotherapy
- Where
- China
- Volunteers
- 209 people
- Sponsor
- Sun Yat-sen University
Oligometastatic Disease, Non-small Cell Lung Cancer
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
- Conditions
- Oligometastatic Disease, Non-small Cell Lung Cancer, Driver Mutation
- Trial name
- TARGET-01 (NCT05277844)
- Testing
- Local Consolidative Radiation Therapy, TKI
- Where
- India
- Volunteers
- 106 people
- Sponsor
- Tata Memorial Hospital
Stage 4 NSCLC, Radiotherapy
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
- Trial name
- DRO2301 (NCT06262321)
- Testing
- Prophylactic Palliative Radiotherapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Rochester
Locally Advanced Solid Tumors, Metastatic Solid Tumors
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult…
- Trial name
- TRIDENT-1 (NCT03093116)
- Testing
- Oral repotrectinib (TPX-0005)
- Where
- 165 sites in United States, Australia and 17 more
- Volunteers
- 500 people
- Sponsor
- Turning Point Therapeutics, Inc.
NSCLC, NSCLC Stage IV
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
This is a prospective, non-randomized, single arm, single institution phase II trial to evaluate the safety and effectiveness of stereotactic ablative radiotherapy (SABR) in oncogene addicted and non-oncogene addicted synchronous…
- Conditions
- NSCLC, NSCLC Stage IV, Oligometastatic Disease, Non Small Cell Lung Cancer
- Trial name
- STARTNEWERA-OM (NCT06207292)
- Testing
- Stereotactic Ablative Radiotherapy
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Radiotherapy Oncology Centre "Santa Maria" Hospital
Lung Cancer (NSCLC), Leptomeningeal Metastasis
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC
This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.
- Trial name
- NCT06663306
- Testing
- Pemetrexed, Bevacizumab
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer, Metastatic Cancer
Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer
The aim of this study is to explore the efficacy and toxicity of icotinib combined with WBRT in treating patients with multiple brain metastases from NSCLC.
- Trial name
- NCT01514877
- Testing
- Icotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Liver Metastases, Non-small Cell Lung Cancer
Liver SBRT in Combination With Immune Checkpoint Inhibition in Patients With Metastatic Non-small Cell Lung Cancer
Determine the feasibility of liver stereotactic body radiation therapy (SBRT) given in combination with systemic therapy (immune checkpoint inhibitors) in adult patients with metastatic NSCLC with liver metastases.
- Trial name
- NCT05430009
- Testing
- Liver SBRT, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- VA Ann Arbor Healthcare System
Lung Cancer
Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer
A prospective, observational, single-center study to determine the proportion of patients who have or will develop changes in biological markers of immunity during immunotherapy treatment.
- Trial name
- IMMUNO-PREDICT (NCT04918836)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Brest
Stage IIIB Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Circulating Tumor Cells in Lung Cancer
TITLE : Circulating tumor cells identification in advanced stage non-small cell lung cancer (CIRCUBRONCH) BACKGROUND : Circulating tumor cells identification is a new field of research in oncology, and some studies have been…
- Trial name
- CIRCUBRONCH (NCT01658332)
- Testing
- blood samples
- Where
- France
- Volunteers
- 59 people
- Sponsor
- Central Hospital, Nancy, France
Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
This phase I trial studies the side effects of atezolizumab, varlilumab, and radiation therapy in treating patients with non-small cell lung cancer that has spread to other places in the body (advanced) and cannot be removed by…
- Trial name
- NCT04081688
- Testing
- Atezolizumab 1200 MG in 20 ML Injection, Stereotactic Body Radiation Therapy, Varlilumab 3 mg/kg
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Rutgers, The State University of New Jersey
Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy
This phase II trial studies how well MLN4924 (pevonedistat), carboplatin, and paclitaxel work in treating patients with stage IIIB or IV non-small cell lung cancer.
- Conditions
- Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Trial name
- NCT03965689
- Testing
- Carboplatin, Paclitaxel, Pevonedistat
- Where
- 10 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Lung Neoplasms, Lung Cancer
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
Medically inoperable lung cancer or metastatic lung tumours will be treated with fractionated stereotactic radiation using a schedule of 1) 12 Gy x 4 treatments or 2) 6 Gy x 10 treatments.
- Trial name
- NCT00351962
- Testing
- Fractionated Stereotactic Radiotherapy
- Where
- Canada
- Volunteers
- 58 people
- Sponsor
- AHS Cancer Control Alberta
Squamous Non-Small Cell Lung Cancer (NSCLC)
Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of the study is to evaluate the effectiveness of zanzalintinib in combination with pembrolizumab as first-line maintenance therapy in participants with metastatic squamous NSCLC.
- Trial name
- STELLAR-202 (NCT07845786)
- Testing
- Carboplatin, Paclitaxel, Nab-paclitaxel
- Volunteers
- 60 people
- Sponsor
- Exelixis
Non Small Cell Lung Cancer, Metastatic Melanoma
UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade
This is a phase I/II study that will evaluate the safety and toxicity of this combinatorial approach. Eligible patients >18 years of age with histologically proven metastatic NSCLC, melanoma, RCC, or HNSCC who have failed PD-1 /…
- Conditions
- Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03474497
- Testing
- IL-2, Pembrolizumab, Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Megan Daly, MD
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation
This phase I/Ib trial studies the side effects and best doses of capmatinib plus trametinib when given together for the treatment of patients with MET exon 14 skipping mutation non-small cell lung cancer that has spread to other…
- Trial name
- NCT05435846
- Testing
- Capmatinib, Trametinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Collin Blakely
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.
- Conditions
- Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer)
- Trial name
- NCT06835569
- Testing
- ALTA3263, cetuximab, mFOLFOX6
- Where
- 14 sites in United States
- Volunteers
- 448 people
- Sponsor
- Alterome Therapeutics, Inc.
Non Small Cell Lung Cancer
A Prospective, Multicenter, Non-interventional, Real-world Study to Characterize Changes in Molecular Markers After Three Weeks of Targeted Therapy With Oxitinib in EGFRm NSCLC
To evaluate the characteristics of genetic variationmutations at baseline and 3 weeks after oxitinib treatment in EGFRm NSCLC
- Trial name
- pre-FLAME (NCT06422546)
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Beijing Cancer Prevention & Treatment Society
Melanoma, Non-Small Cell Lung Cancer
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
The purpose of this trial is to study the activity of MK-3475 in untreated brain metastases from melanoma or non-small cell lung cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Brain Metastases
- Trial name
- NCT02085070
- Testing
- MK-3475
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Yale University
Metastatic Non-Small Cell Lung Cancer
Real-World Assessment of Clinical Outcomes in Metastatic NSCLC Patients With MET Exon 14 Skipping Mutation and Brain Metastases Treated With Capmatinib
This was a retrospective, noninterventional cohort study of patients with a confirmed diagnosis of metastatic NSCLC with MET Exon 14 skipping mutation and brain metastases (BM) who received treatment with capmatinib in real-world…
- Trial name
- NCT05675683
- Testing
- Capmatinib
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals